Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice

Respiration

Volumn 82, Issue 3, 2011, Pages 273-287

  Rhee, Chin Kook ^a   Lee, Sang Haak ^a   Yoon, Hyung Kyu ^a   Kim, Seok Chan ^a   Lee, Sook Young ^a   Kwon, Soon Suk ^a   Kim, Young Kyoon ^a   Kim, Kwan Hyoung ^a   Kim, Tae Jung ^b   Kim, Jin Woo ^a  

^a Uijeongbu St Mary's Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Acute lung injury; Imatinib; Nilotinib; Platelet derived growth factor; Pulmonary fibrosis; Transforming growth factor

Indexed keywords

BLEOMYCIN; HYDROXYPROLINE; IMATINIB; INTERLEUKIN 1BETA; INTERLEUKIN 6; NILOTINIB; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; HISTOPATHOLOGY; IN VITRO STUDY; INFLAMMATORY CELL; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG PARENCHYMA; LYMPHOCYTE; MACROPHAGE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACUTE LUNG INJURY; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; BLOTTING, WESTERN; GENE EXPRESSION REGULATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MICE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PULMONARY FIBROSIS; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051786966     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000327719     Document Type: Article

References (55)

1. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-1349. (Pubitemid 30408719)
2. Anonymous: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342: 1301-1308.
3. Lamy M, Fallat RJ, Koeniger E, Dietrich HP, Ratliff JL, Eberhart RC, Tucker HJ, Hill JD: Pathologic features and mechanisms of hypoxemia in adult respiratory distress syndrome. Am Rev Respir Dis 1976; 114: 267-284.
4. Tomashefski JF: Pulmonary pathology of the adult respiratory distress syndrome. Clin Chest Med 1990; 11: 593-619.
5. Moore B, Hogaboam CM: Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294:L152-L160. (Pubitemid 351253350)
6. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon F, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002; 99: 1928-1937. (Pubitemid 34525471)
7. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037. (Pubitemid 32267972)
8. Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyer T, Zimmermann J: Imatinib: A selective tyrosine kinase inhibitor. Eur J Cancer 2002; 38(suppl 5):S19-S27.
9. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, Walker C, Jarai G: Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008; 599: 44-53.
10. Pardanani A, Reeder T, Porrata LF, Li C, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A: Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101: 3391-3397. (Pubitemid 36857919)
11. Coutr S, Gotlib J: Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Semin Cancer Biol 2004; 14: 307-315. (Pubitemid 39419476)
12. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R: Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003; 100: 7830-7835. (Pubitemid 36760055)
13. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-2551. (Pubitemid 43882350)
14. Manley PW, Cowan-Jacob SW, Mestan J: Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 2005; 1754: 3-13. (Pubitemid 41797682)
15. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Mohammed A, Neuberg D, Wright RD, Gilliland DG, Griffin JD: Characterization of AMN107, a selective inhibitor of native and mutant Bcr- Abl. Cancer Cell 2005; 7: 129-141. (Pubitemid 40248339)
16. Aono Y, Nishioka Y, Inayama M, Ugai M, Kishi J, Uehara H, Izumi K, Sone S: Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005; 171: 1279-1285. (Pubitemid 40740736)
17. Murao Y, Loomis W, Wolf P, Hoyt DB, Junger WG: Effect of dose of hypertonic saline on its potential to prevent lung tissue damage in a mouse model of hemorrhagic shock. Shock 2003; 20: 29-34.
18. Ashcroft T, Simpson JM, Timbrell V: Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41: 467-470. (Pubitemid 18098428)
19. T method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
20. Cutroneo KR, Sterling KM: A molecular basis for bleomycin-induced pulmonary fibrosis. Chest 1986; 89: 121S-122S. (Pubitemid 16105320)
21. Aoki Y, Maeno T, Aoyagi K, Ueno M, Aoki F, Aoki N, Nakagawa J, Sando Y, Shimizu Y, Suga T, Arai M, Kurabayashi M: Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin- induced acute lung injury and fibrosis. Respiration 2009; 77: 311-319.
22. Chaudhary NI, Schnapp A, Park JE: Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006; 173: 769-776.
23. Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R: Time course of bleomycininduced lung fibrosis. Int J Exp Pathol 2002; 83: 111-119. (Pubitemid 35286131)
24. Janick-Buckner D, Ranges GE, Hacker MP: Alteration of bronchoalveolar lavage cell populations following bleomycin treatment in mice. Toxicol Appl Pharmacol 1989; 100: 465-473. (Pubitemid 19253924)
25. Miyachi K, Ihara A, Hankins RW, Murai R, Maehiro S, Miyashita H: Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 2003; 22: 329-332. (Pubitemid 37483630)
26. Eklund K, Joensuu H: Treatment of rheumatoid arthritis with imatinib mesylate: Clinical improvement in three refractory cases. Ann Med 2003; 35: 362-367. (Pubitemid 37013677)
27. Eklund K, Lindstedt K, Sandler C, Kovanen PT, Laasonen L, Juurikivi A, Wolff H, Mykknen M, Joensuu H: Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis. J Clin Rheumatol 2008; 14: 294-296.
28. Koyama K, Hatsushika K, Ando T, Sakuma M, Wako M, Kato R, Haro H, Sugiyama H, Hamada Y, Ogawa H, Nakao A: Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. Mod Rheumatol 2007; 17: 306-310. (Pubitemid 47263822)
29. Wolf AM, Wolf D, Rumpold H, Ludwiczek S, Enrich B, Gastl G, Weiss G, Tilg H: The kinase inhibitor imatinib mesylate inhibits TNF- β production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci USA 2005; 102: 13622-13627. (Pubitemid 41420898)
30. Fahy RJ, Lichtenberger F, McKeegan CB, Nuovo GJ, Marsh CB, Wewers MD: The acute respiratory distress syndrome: A role for transforming growth factor-beta 1. Am J Respir Cell Mol Biol 2003; 28: 499-503. (Pubitemid 36399372)
31. Martin C, Papazian L, Payan MJ, Saux P, Gouin F: Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome. A study in mechanically ventilated patients. Chest 1995; 107: 196-200.
32. Heldin CH, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-1316. (Pubitemid 29473317)
33. Jantz MA, Antony VB: Pathophysiology of the pleura. Respiration 2008; 75: 121-133. (Pubitemid 351363863)
34. Antoniades HN, Bravo MA, Avila RE, Galanopoulos T, Neville-Golden J, Maxwell M, Selman M: Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990; 86: 1055-1064. (Pubitemid 20370408)
35. Homma S, Nagaoka I, Abe H, Takahashi K, Seyama K, Nukiwa T, Kira S: Localization of platelet-derived growth factor and insulinlike growth factor I in the fibrotic lung. Am J Respir Crit Care Med 1995; 152: 2084-2089.
36. Aubert JD, Pare PD, Hogg JC, Hayashi S: Platelet-derived growth factor in bronchiolitis obliterans-organizing pneumonia. Am J Respir Crit Care Med 1997; 155: 676-681. (Pubitemid 27085819)
37. Hertz MI, Henke CA, Nakhleh RE, Harmon KR, Marinelli WA, Fox JM, Kubo SH, Shumway SJ, Bolman RM, Bitterman PB: Obliterative bronchiolitis after lung transplantation: A fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad Sci USA 1992; 89: 10385-10389.
38. Uebelhoer M, Bewig B, Kreipe H, Nowak D, Magnussen H, Barth J: Modulation of fibroblast activity in histiocytosis X by plateletderived growth factor. Chest 1995; 107: 701-705.
39. Vanhee D, Gosset P, Wallaert B, Voisin C, Tonnel AB: Mechanisms of fibrosis in coal workers' pneumoconiosis. Increased production of platelet-derived growth factor, insulin-like growth factor type I, and transforming growth factor β and relationship to disease severity. Am J Respir Crit Care Med 1994; 150: 1049-1055.
40. Yoshida M, Sakuma-Mochizuki J, Abe K, Arai T, Mori M, Goya S, Matsuoka H, Hayashi S, Kaneda Y, Kishimoto T: In vivo gene transfer of an extracellular domain of platelet- derived growth factor beta receptor by the HVJ-liposome method ameliorates bleomycin- induced pulmonary fibrosis. Biochem Biophys Res Commun 1999; 265: 503-508.
41. Rice AB, Moomaw CR, Morgan DL, Bonner JC: Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol 1999; 155: 213-221. (Pubitemid 29318719)
42. Gharaee-Kermani M, Hu B, Phan SH, Gyetko MR: Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: Focus on TGF β signaling and the myofibroblast. Curr Med Chem 2009; 16: 1400-1417.
43. Gorelik L, Flavell RA: Transforming growth factor- β in T-cell biology. Nat Rev Immunol 2002; 2: 46-53. (Pubitemid 37328775)
44. Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210. (Pubitemid 351160157)
45. Gauldie J, Bonniaud P, Sime P, Ask K, Kolb M: TGF- β , Smad3 and the process of progressive fibrosis. Biochem Soc Trans 2007; 35: 661-664. (Pubitemid 47310335)
46. Roberts AB, Tian F, Byfield SD, Stuelten C, Ooshima A, Saika S, Flanders KC: Smad3 is key to TGF- β -mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine 2006; 17: 19-27. (Pubitemid 43117513)
47. Lee SY, Kim JS, Lee JM, Kwon SS, Kim KH, Moon HS, Song JS, Park SH, Kim YK: Inhaled corticosteroid prevents the thickening of airway smooth muscle in murine model of chronic asthma. Pulm Pharmacol 2008; 21: 14-19.
48. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB: Imatinib mesylate inhibits the profibrogenic activity of TGF- β and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308-1316. (Pubitemid 40385302)
49. Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jngel A, Zwerina J, Gay S, Schett G, Distler O, Distler JH: Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008; 22: 2214-2222. (Pubitemid 351948641)
50. Giri SN, Hyde DM, Hollinger MA: Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice. Thorax 1993; 48: 959-966. (Pubitemid 23319618)
51. Broekelmann TJ, Limper AH, Colby TV, Mc- Donald JA: Transforming growth factor β 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991; 88: 6642-6646. (Pubitemid 21915005)
52. Dhainaut J, Charpentier J, Chiche J: Transforming growth factor- β : A mediator of cell regulation in acute respiratory distress syndrome. Crit Care Med 2003; 31:S258-S264. (Pubitemid 36458177)
53. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR: Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181: 604-610.
54. Shaker ME, Salem HA, Shiha GE, Ibrahim TM: Nilotinib counteracts thioacetamideinduced hepatic oxidative stress and attenuates liver fibrosis progression. Fundam Clin Pharmacol 2011; 25: 248-257.
55. Weisberg E, Wright RD, Jiang J, Ray A, Moreno D, Manley PW, Fabbro D, Hall-Meyers E, Catley L, Podar K, Kung AL, Griffin JD: Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 2006; 131: 1734-1742. (Pubitemid 44958515)